Background: Population-based studies on endometrial cancer providing survival estimates by age, histology, and\r\nstage have been sparse. We aimed to derive most up-to-date and detailed survival estimates for endometrial\r\ncancer patients in Germany.\r\nMethods: We used a pooled German national dataset including data from 11 cancer registries covering a\r\npopulation of 33 million people. 30,906 patients diagnosed with endometrial cancer in 1997-2006 were included.\r\nPeriod analysis was performed to calculate 5-year relative survival (RS) in 2002-2006. Trends in survival between\r\n2002 and 2006 were examined using model-based period analysis. Age-adjustment was performed using five age\r\ngroups (15-44, 45-54, 55-64, 65-74, and 75+ years).\r\nResults: Overall, age-adjusted 5-year relative survival in 2002-2006 was 81%. A moderate age gradient was\r\nobserved, with 5-year RS decreasing from 90% in the age group 15-49 years to 75% in the age group 70+ years.\r\nFurthermore prognosis varied strongly by histologic subtypes and stage, with age-adjusted 5-year RS ranging from\r\n43% (for sarcoma) to 94% (for squamous metaplasia), and reaching 91% for localized, 51% for regional, and 20% for\r\ndistant stage. Except for age group 65-74 years, no significant improvement in survival was seen during the recent\r\n5-year period under investigation.\r\nConclusion: In this comprehensive population-based survival analysis of patients with endometrial cancer from\r\nGermany, prognosis of endometrial cancer moderately varied by age, and strongly varied by histology and stage.\r\nWhile prognosis is rather good overall, further improvement in 5-year relative survival of endometrial cancer\r\npatients has been stagnating in the early 21st century
Loading....